Publications by authors named "Judith Deal"

Claim this Profile
D
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor.
Gary M Gallego, Cynthia Palmer, Suvi Orr, Louise Bernier, Ping Chen, Judith G Deal

J Med Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.
Cynthia L Palmer, Britton Boras, Bernadette Pascual, Na Li, Danan Li, Judith G Deal

Cancer Cell· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195).
Hengmiao Cheng, Suvi T M Orr, Simon Bailey, Alexei Brooun, Ping Chen, Judith G Deal

J Med Chem· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of N-((3R,4R)-4-Fluoro-1-(6-((3-methoxy-1-methyl-1H-pyrazol-4-yl)amino)-9-methyl-9H-purin-2-yl)pyrrolidine-3-yl)acrylamide (PF-06747775) through Structure-Based Drug Design: A High Affinity Irreversible Inhibitor Targeting Oncogenic EGFR Mutants with Selectivity over Wild-Type EGFR.
Simon Planken, Douglas C Behenna, Sajiv K Nair, Theodore O Johnson, Asako Nagata, Judith G Deal

J Med Chem· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations.
Ted W Johnson, Paul F Richardson, Simon Bailey, Alexei Brooun, Benjamin J Burke, Judith G Deal

J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.
Qinhua Huang, Ted W Johnson, Simon Bailey, Alexei Brooun, Kevin D Bunker, Judith G Deal

J Med Chem· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Structural modifications of a 3-methoxy-2-aminopyridine compound to reduce potential for mutagenicity and time-dependent drug-drug interaction.
Cynthia Palmer, Mason Pairish, Susan Kephart, Djamal Bouzida, Jingrong Cui, Judith Deal

Bioorg Med Chem Lett· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design, synthesis, and biological activity of novel polycyclic aza-amide FKBP12 ligands.
Raymond A Hudack, Nancy S Barta, Chuangxing Guo, Judith Deal, Liming Dong

J Med Chem· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis